The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.

e19030 Background: Second-line treatment for advanced non-small-cell lung cancer (aNSCLC) patients includes monotherapy with a third generation cytotoxic drug (CT) or with the tyrosine kinase inhibitor (TKI) erlotinib. These options are the actual standard treatment for EGFR gene wild-type (WT) status, as patients with EGFR mutations achieve greater benefit by the use of TKI in first-line treatment. Some prospective clinical trials and meta-analyses investigated the comparison between CT and TKI in second-line, but data are conflicting. Methods: We designed a retrospective trial to gather information about TKI sensitivity in comparison with CT. We selected from clinical records data of patients treated with at least 1 line of CT and at least 1 line of TKI. We collected information about age, sex, performance status, comorbidity, smoking status, histotype, metastatic sites, EGFR mutational status, mutation type, treatment schedule, better response and time-to-progression (TTP) for each line of treatment an...